UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/542,185	10/19/2006	Mostafa Sadoqi	4424-4000US1	7843
	7590 07/14/200 INNEGAN, L.L.P.	80	EXAMINER	
3 WORLD FIN	ANCIAL CENTER		LE, HOA T	
NEW YORK, N	N1 10281-2101		ART UNIT	PAPER NUMBER
			1794	
			NOTIFICATION DATE	DELIVERY MODE
			07/14/2008	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTOPatentCommunications@Morganfinnegan.com Shopkins@Morganfinnegan.com jmedina@Morganfinnegan.com

		Application No.	Applicant(s)			
Office Action Summary		10/542,185	SADOQI ET AL.			
		Examiner	Art Unit			
		H. T. Le	1794			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) 又	Responsive to communication(s) filed on <u>07 A</u>	oril 2008				
· ·	This action is <b>FINAL</b> . 2b) ☐ This action is non-final.					
′=	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
٥,١	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
· · ·		ne annlication				
•	Claim(s) <u>2,14,15 and 19-21</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.					
	_					
	5)  Claim(s) is/are allowed. 6)  Claim(s)					
· ·	Claim(s) is/are objected to.					
•	Claim(s) are subject to restriction and/or	r election requirement				
ا ا	ciaiii(s) are subject to restriction and/or	r election requirement.				
Applicati	on Papers					
9)	The specification is objected to by the Examine	r.				
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority ι	ınder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some col None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
2)  Notic 3)  Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date <u>April 2008</u> .	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

Application/Control Number: 10/542,185 Page 2

Art Unit: 1794

## **DETAILED ACTION**

1. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

## Claim Rejections - 35 USC § 102

2. Claims 2, 14, and 19-21 are rejected under 35 U.S.C. 102(b) as being anticipated by Khoobehi et al (US 5,437,274).

Claims 2, 14 and 15: Khoobehi teaches a nanocapsule or nanosphere comprising a fluorescent dye encapsulated in a polymer wall of polylactic acid (PLA), polyglycolic acid (PGA) or copolymer of ethylene-vinyl-acetate (PVA). See col. 4, lines 46-59 and col. 6, lines 54-63. The fluorescent dye is preferably chosen from indocyanine green (ICG) (col. 5, lines 6-11).

Claims 19-21: The properties as claimed are deemed met by inherence because the nanocapsule or nanosphere taught by Khoobehi comprises the same substance and has the same structure as the composition of the claimed invention.

- 3. Claim 15 is rejected under 35 U.S.C. 102(b) as being anticipated by Shaw (US 6,695,870).
- 4. Shaw teaches the nanocapsule or nanosphere of Khoobehi (US 5,437,274) that is a nanosphere comprising a fluorescent dye encapsulated in a polymer wall of polylactic acid (PLA), polyglycolic acid (PGA) or copolymer of ethylene-vinyl-acetate (PVA). See Shaw, col. 4, line 59 to col. 5, line 10 and col. 6, lines 45-53. The nanocapsule or nanosphere is used to treat diseased tissues, e.g. tumors. See col. 1, lines 10-18 and 61-67; col. 7, lines 60-66; and claim 1.

Application/Control Number: 10/542,185 Page 3

Art Unit: 1794

## Conclusion

5. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to H. T. Le whose telephone number is 571-272-1511. The examiner can normally be reached on 9:30 a.m. to 6:00 p.m., Mondays to Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Rena Dye can be reached on 571-272-3186. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/542,185 Page 4

Art Unit: 1794

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/H. (Holly) T. Le/ Primary Examiner, Art Unit 1794

July 7, 2008